A Psychological Bulletin review of 307 studies finds rising perfectionism among college students, with sharp increases in worry over mistakes and socially prescribed pressure.

Starting July 1, 2026, Medicare’s GLP‑1 Bridge will let select Part D enrollees get Wegovy, Zepbound or Foundayo for $50 a month — but strict BMI and health rules apply.

A University of Georgia meta‑analysis found tirzepatide produced the largest weight loss among GLP‑1 therapies in non‑diabetic adults, but questions remain on durability and access.

UNLV researchers were among co‑authors of a GBD study published in Med that finds the U.S. had the highest substance use disorder prevalence in 2023 and projects increases to 2050 without intervention.

A national ABCD study finds early heavy social media use tied to much higher odds that teens will try alcohol, nicotine and cannabis.

Unregulated injectable peptides marketed online are rising among teens and young men in DC, prompting warnings from doctors and federal regulators. Clinicians and the FDA say the risks go beyond marketing claims.

Certain duloxetine (generic Cymbalta) lots were recalled after tests found a nitrosamine impurity; regulators and pharmacists advise checking NDCs and talking to your prescriber.

A biomarker analysis of more than 30,000 adults found that most people who meet the 'five-a-day' guideline still fall short of the 500 mg/day flavanol level linked to lower heart deaths.

MedStar will close one postpartum unit at Washington Hospital Center, cutting 11 beds and displacing staff as the system cites financial pressures while union and community leaders push back.

The FDA added bemotrizinol to the U.S. sunscreen monograph, the first new active allowed since the 1990s; DSM gets limited exclusivity and products are expected later this year.

A new federally commissioned study finds health risks rise after one drink a day and recommends one drink or fewer, while the 202520130 Dietary Guidelines omitted numeric limits.

Cigna will end coverage of GLP‑1 weight‑loss medications for employees on July 1, pushing staff toward cash payments and manufacturer or federal discount programs. The move follows price shifts driven by new oral pills and the Medicare Bridge.

Target recalled select Up & Up baby wipes after lab tests found Burkholderia bacteria. Parents should check pack codes and stop using affected wipes.